Form 8-K Silo Pharma, Inc. For: Feb 02
- Wall St listless as investors await Fed rate decision, Powell comments
- Fed Day: '25bps seems the most likely, and best outcome' - JPMorgan
- Fed in spotlight with focus on rate rises, bank stability
- PacWest says it would not be 'prudent' to go ahead with capital raise
- Meme stocks rally after GameStop posts surprise fourth-quarter profit
Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
|(State or other jurisdiction
|(Commission File Number)||(IRS Employer|
|(Address of principal executive offices)||(Zip Code)|
Registrant’s telephone number, including
area code: (
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
|Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)|
|Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)|
|Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))|
|Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))|
Securities registered pursuant to Rule 12(b) of the Act:
|Title of each class||Trading Symbol(s)||Name of exchange on which registered|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 8.01 – Other Events
On February 2, 2023, Silo Pharma, Inc. (the “Company”) issued a press release announcing that the U.S. Patent and Trademark Office (“USPTO”) issued a new patent covering the Company’s portfolio therapy SPC-15. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
|99.1||Press release dated February 2, 2023|
|104||Cover Page Interactive Data File (embedded within the Inline XBRL document)|
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|SILO PHARMA, INC.|
|Date: February 3, 2023||By:||/s/ Eric Weisblum|
|Chief Executive Officer|
ATTACHMENTS / EXHIBITS
PRESS RELEASE DATED FEBRUARY 2, 2023
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Silo Pharma (SILO) Announces Positive Results from IND-Enabling Study of SP-26 for Fibromyalgia
- Digitizing Payments and Improving Payment Terms Top Priorities of German Businesses to Offset Current Economic Headwinds, Shows Rapyd Report
- Mining Interest in Fertilizer Production Increases
Create E-mail Alert Related CategoriesSEC Filings
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!